Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

Roche boosts its antibody arsenal with a $489M buyout

Roche is betting big on antibodies that can attack two targets at once, signing on to buy Austria's Dutalys for as much as $488.8 million and get its hands on some proprietary technology.

Lundbeck pulls the plug on its fast-tracked stroke drug

Lundbeck is giving up on its efforts to develop desmoteplase as a treatment for stroke, as disappointing data have made it unclear just how to proceed.

Bellicum pulls off a $140M IPO as CAR-T has its day on Wall Street

Bellicum Pharmaceuticals, at work in oncology's buzziest field, banked $140 million in an upsized, above-its-range IPO, stoking the fervor around cancer immunotherapies.

Padlock banks $23M with a fresh approach to autoimmune disease

Startup Padlock Therapeutics has a novel approach to autoimmune disease that could reduce the need for immunosuppressants, and the biotech has $23 million in fresh cash to explore the idea.

Biopharma's R&D budgets stay about flat amid global cuts

Thanks to global downsizing, the rapid rise of CROs and mounting pricing pressures, the R&D spends of the world's biggest drug developers remained flat last year, according to a report.

J&J rents Halozyme's R&D technology for up to $581M

Johnson & Johnson has signed a deal to use Halozyme Therapeutics' drug delivery platform in its own R&D efforts, agreeing to pay as much as $581 million for the privilege.

Pozen gets another FDA cold shoulder for its cardio drugs

The FDA again rejected Pozen's pair of treatments designed to help patients deal with cardiovascular disease, citing the same third-party manufacturing issues that tanked the last application. Pozen claims the supplier has since rectified those concerns but that the agency has been less than cooperative in the process.

Auspex shares rocket up after Huntington's drug hits the mark in Phase III

Auspex Pharmaceuticals' treatment for a movement disorder tied to Huntington's disease met its main goal in a late-stage study, the company said, clearing the way for a 2015 FDA filing.

Google Ventures splashes into life sciences with its $425M purse

Google Ventures is betting more and more on life sciences startups each year, and the well-funded financier tells The Wall Street Journal that's not going to change in the new year.

Cyclacel's cancer drug isn't working in Phase III, but that won't stop the trial

Cyclacel Pharmaceuticals' in-development leukemia drug has little chance of meeting its primary goal in a late-stage study, independent advisers said. But, because the treatment isn't leading to serious side effects, the company is keeping the trial running.